| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
2-Aminopurine's nucleic acid base is greatly quenched by trona when it is incorporated into an oligonucleotide, making it unavailable as a nucleic acid marker. But the precise and accurate fluorescent label for nucleic acid structures is 2-aminopurine, thanks to its extremely sensitive property to inter-base quenching [1]. 6-aminopurine differs from 2-aminopurine merely in the position outside the ring, but its fluorescence intensity is hundreds of times greater than that of purine and adenine [1].
|
|---|---|
| References |
|
| Additional Infomation |
2-aminopurine is the parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position. It has a role as an antimetabolite. It is a member of 2-aminopurines and a nucleobase analogue.
A purine that is an isomer of ADENINE (6-aminopurine). |
| Molecular Formula |
C5H5N5
|
|---|---|
| Molecular Weight |
135.1267
|
| Exact Mass |
135.054
|
| CAS # |
452-06-2
|
| Related CAS # |
2-Aminopurine dihydrochloride;1428126-74-2
|
| PubChem CID |
9955
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
328.2±25.0 °C at 760 mmHg
|
| Melting Point |
280-282 °C(lit.)
|
| Flash Point |
152.3±23.2 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.954
|
| LogP |
-1.33
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
127
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MWBWWFOAEOYUST-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5N5/c6-5-7-1-3-4(10-5)9-2-8-3/h1-2H,(H3,6,7,8,9,10)
|
| Chemical Name |
7H-purin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~37.00 mM)
H2O : ~1.35 mg/mL (~9.99 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (18.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.4003 mL | 37.0014 mL | 74.0028 mL | |
| 5 mM | 1.4801 mL | 7.4003 mL | 14.8006 mL | |
| 10 mM | 0.7400 mL | 3.7001 mL | 7.4003 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06210750 | WITHDRAWN | Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy |
T Acute Lymphoblastic Leukemia T Lymphoblastic Lymphoma |
National Cancer Institute (NCI) | 2024-08-09 | Phase 2 |
| NCT02521493 | ACTIVE, NOT RECRUITING | Drug: Asparaginase Drug: Asparaginase Erwinia chrysanthemi Drug: Cytarabine |
Acute Myeloid Leukemia Down Syndrome Myelodysplastic Syndrome Myeloid Leukemia Associated With Down Syndrome Myeloproliferative Neoplasm |
Children's Oncology Group | 2015-12-23 | Phase 3 |
| NCT04546399 | SUSPENDED | Radiation: 3-Dimensional Conformal Radiation Therapy Biological: Blinatumomab Drug: Cyclophosphamide |
Down Syndrome Recurrent B Acute Lymphoblastic Leukemia |
National Cancer Institute (NCI) | 2020-12-04 | Phase 2 |
| NCT03007147 | ACTIVE, NOT RECRUITING | Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Calaspargase Pegol Drug: Cyclophosphamide |
Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia |
Children's Oncology Group | 2017-08-08 | Phase 3 |
| NCT06317662 | NOT YET RECRUITING | Drug: Asparaginase Erwinia chrysanthemi Procedure: Biospecimen Collection Biological: Blinatumomab |
Acute Leukemia of Ambiguous Lineage B Acute Lymphoblastic Leukemia |
National Cancer Institute (NCI) | 2024-10-28 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
